Matches in SemOpenAlex for { <https://semopenalex.org/work/W1954193773> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W1954193773 endingPage "1054" @default.
- W1954193773 startingPage "1054" @default.
- W1954193773 abstract "<h3>Objective</h3> To evaluate the efficacy and safety of tabalumab, a monoclonal antibody that neutralises membrane-bound and soluble B-cell activating factor (BAFF), in patients with active rheumatoid arthritis (RA) who showed inadequate response to tumour necrosis factor (TNF) inhibitors. <h3>Methods</h3> Patients on stable methotrexate and with inadequate response to one or more TNF inhibitors were randomised to placebo (n=35), 30 mg tabalumab (n=35) or 80 mg tabalumab (n=30) given intravenously at 0, 3 and 6 weeks. The primary outcome was the proportion of patients achieving an American College of Rheumatology 50% response (ACR50) at week 16 (all tabalumab-treated patients vs placebo). <h3>Results</h3> At week 16, no significant differences were observed in the combined tabalumab group versus placebo in ACR50 (12.7% vs 2.9%, p=0.101) or ACR20 response rates (27.0% vs 17.1%, p=0.198). However, significant differences between the combined tabalumab group and placebo were observed at earlier time points for ACR20, ACR50 and Disease Activity Score in 28 joints (DAS28)-C-reactive protein (CRP) reduction. Treatment-emergent adverse events (AEs) were similar with 30 mg tabalumab (65.7%), 80 mg tabalumab (76.7%) and placebo (71.4%), although certain events occurred more often with tabalumab than placebo (eg, infection, anaemia and gastrointestinal events). Serious AEs occurred in two (6.7%) patients receiving 80 mg tabalumab and three (8.6%) receiving placebo, with one serious infection in the placebo group. Initial increases in total and mature B cells were followed by progressive decreases, despite declines in serum tabalumab. <h3>Conclusions</h3> At week 16, the primary end point was not achieved, but an indication of efficacy was observed at earlier time points. Safety findings for tabalumab were consistent with other biological RA therapies. <h3>Clinical trial registration number</h3> NCT00689728." @default.
- W1954193773 created "2016-06-24" @default.
- W1954193773 creator A5070810586 @default.
- W1954193773 date "2004-12-01" @default.
- W1954193773 modified "2023-10-02" @default.
- W1954193773 title "Relation of rainfall pattern and epidemic leptospirosis in the Indian state of Kerala" @default.
- W1954193773 cites W2013122637 @default.
- W1954193773 cites W2040853768 @default.
- W1954193773 cites W2104026547 @default.
- W1954193773 doi "https://doi.org/10.1136/jech.2003.018556" @default.
- W1954193773 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1732659" @default.
- W1954193773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15547074" @default.
- W1954193773 hasPublicationYear "2004" @default.
- W1954193773 type Work @default.
- W1954193773 sameAs 1954193773 @default.
- W1954193773 citedByCount "39" @default.
- W1954193773 countsByYear W19541937732012 @default.
- W1954193773 countsByYear W19541937732013 @default.
- W1954193773 countsByYear W19541937732015 @default.
- W1954193773 countsByYear W19541937732016 @default.
- W1954193773 countsByYear W19541937732017 @default.
- W1954193773 countsByYear W19541937732018 @default.
- W1954193773 countsByYear W19541937732019 @default.
- W1954193773 countsByYear W19541937732020 @default.
- W1954193773 countsByYear W19541937732021 @default.
- W1954193773 countsByYear W19541937732022 @default.
- W1954193773 crossrefType "journal-article" @default.
- W1954193773 hasAuthorship W1954193773A5070810586 @default.
- W1954193773 hasBestOaLocation W19541937731 @default.
- W1954193773 hasConcept C11413529 @default.
- W1954193773 hasConcept C124101348 @default.
- W1954193773 hasConcept C25343380 @default.
- W1954193773 hasConcept C2778033228 @default.
- W1954193773 hasConcept C41008148 @default.
- W1954193773 hasConcept C42972112 @default.
- W1954193773 hasConcept C48103436 @default.
- W1954193773 hasConcept C71924100 @default.
- W1954193773 hasConcept C99454951 @default.
- W1954193773 hasConceptScore W1954193773C11413529 @default.
- W1954193773 hasConceptScore W1954193773C124101348 @default.
- W1954193773 hasConceptScore W1954193773C25343380 @default.
- W1954193773 hasConceptScore W1954193773C2778033228 @default.
- W1954193773 hasConceptScore W1954193773C41008148 @default.
- W1954193773 hasConceptScore W1954193773C42972112 @default.
- W1954193773 hasConceptScore W1954193773C48103436 @default.
- W1954193773 hasConceptScore W1954193773C71924100 @default.
- W1954193773 hasConceptScore W1954193773C99454951 @default.
- W1954193773 hasIssue "12" @default.
- W1954193773 hasLocation W19541937731 @default.
- W1954193773 hasLocation W19541937732 @default.
- W1954193773 hasLocation W19541937733 @default.
- W1954193773 hasLocation W19541937734 @default.
- W1954193773 hasLocation W19541937735 @default.
- W1954193773 hasOpenAccess W1954193773 @default.
- W1954193773 hasPrimaryLocation W19541937731 @default.
- W1954193773 hasRelatedWork W1568752206 @default.
- W1954193773 hasRelatedWork W1871321167 @default.
- W1954193773 hasRelatedWork W1899489728 @default.
- W1954193773 hasRelatedWork W2042668097 @default.
- W1954193773 hasRelatedWork W2169574482 @default.
- W1954193773 hasRelatedWork W2400945722 @default.
- W1954193773 hasRelatedWork W2621420296 @default.
- W1954193773 hasRelatedWork W2903388905 @default.
- W1954193773 hasRelatedWork W3033134072 @default.
- W1954193773 hasRelatedWork W3046703944 @default.
- W1954193773 hasVolume "58" @default.
- W1954193773 isParatext "false" @default.
- W1954193773 isRetracted "false" @default.
- W1954193773 magId "1954193773" @default.
- W1954193773 workType "article" @default.